English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsOpinionAurobindo Pharma’s Cronus rethink is positive, but it needs to do more

    Aurobindo Pharma’s Cronus rethink is positive, but it needs to do more

    Aurobindo Pharma terminated an agreement to acquire a majority stake in Cronus Pharma after the proposal stoked capital allocation concerns

    R. Sree Ram
    August 24, 2021 / 09:30 IST
    Aurobindo Pharma’s Cronus rethink is positive, but it needs to do more

    Representative image

    • PRO Panorama

      Moneycontrol Pro Panorama | Fee fallout

      Sep 22, 2025 / 04:11 PM IST

      In Moneycontrol Pro Panorama September 22 edition: Rahul Gandhi’s election integrity campaign grabs attention, NTPC should flex ...

      Read Now
    Unlock This Article

    Are you a PRO subscriber? Sign In

    What Do You Get

    • Ad free Experience

      Seamless navigation, faster responses.

    • Expert Perspective

      Explore 230+ exclusive editorials every month

    • +

      Uncover Insights from World-Renowned Experts and Journalists

    • Actionable Insights

      40+ weekly investment ideas + 3 to 4 daily technical calls

    • Virtual Events

      Exclusive Live Webinars for Expert Trading & Investment Strategies!

    • Newsletters

      Stay ahead with daily and weekly insights

    View Offers

    Unlock exclusive discounts